Our team has a deep understanding of the regulatory frameworks and submission processes of major authorities, including the FDA and EMA. This enables us to effectively avoid common pitfalls in regulatory matters and address regulatory inquiries, thereby accelerating the market launch of pet drugs.
We have established five innovative technology platforms. These platforms can not only be applied independently but also work synergistically to provide robust technical support for the development of small molecule drugs, antibodies, and vaccines. This enables us to create differentiated and advanced therapies for various diseases.
We operate a modern production facility that complies with GMP standards and can meet production needs of varying scales. A rigorous quality control system has been implemented to ensure consistency in the purity, potency, and stability of every product batch.
We recognize that each client's project is unique and offer flexible collaboration models accordingly. A dedicated project manager is assigned to every project to ensure smooth communication and timely responses, working closely with you to overcome challenges and drive project success.
Protheragen Vetivio has established a library of pet disease models covering a wide range of spontaneous and induced diseases in canine and feline, which can more accurately simulate the pathogenesis and progression of pet diseases, providing precise and reliable data support for new drug screening and efficacy evaluation.
Protheragen Vetivio provides comprehensive preclinical research services, including pharmacokinetics (PK), pharmacodynamics (PD), toxicology, and safety evaluations. These services deliver reliable data support for clinical studies and enhance the probability of pet drugs successfully passing clinical trials.
Protheragen Vetivio boasts extensive clinical trial experience in the field of pet diseases, offering comprehensive clinical research services. Our services comply with rigorous international standards, ensuring the delivery of scientifically reliable clinical data.
Protheragen Vetivio has multiple production lines capable of manufacturing pet drugs in a variety of dosage forms, including tablets, capsules, granules, and injections. Our manufacturing strictly adheres to cGMP standards, ensuring exceptional stability and consistency in every batch of pet drugs.
Protheragen Vetivio has a deep understanding of the requirements of major global regulatory agencies and offers one-stop regulatory services from early development to post-marketing. We help mitigate risks during the pet drug development process and accelerate the time-to-market for pet drugs.
As a globally leading pet drug CRO/CDMO, Protheragen Vetivio deeply understands the uniqueness and complexities of pet drug development. We provide comprehensive services covering the entire pet drug lifecycle, accelerating the market availability of safe and effective pet medications, extending pets' healthy lifespan, and enhancing their quality of life.
Learn More
The flash-release tablet is a revolutionary oral solid dosage form that utilizes freeze-dried flash-release technology. It dissolves rapidly in the mouth without the need for water, significantly improving medication compliance while perfectly preserving the stability of active ingredients. It is particularly suitable for cats, small dogs, and elderly pets.
The oral thin film is a dissolvable polymer strip placed on the pet’s tongue or inside the cheek pouch, dissolving within seconds without the need for water or chewing. This greatly enhances medication compliance in pets and is particularly suitable for small-molecule drugs that require frequent administration or precise dosing.
These are designed as highly-specific "biologic missiles" that precisely target disease-causing proteins in pets (such as inflammatory factors or tumor markers). They enable long-lasting treatment with minimal side effects, significantly improving outcomes for allergic dermatitis, autoimmune diseases, and cancer in dogs and cats.
mRNA acts as a set of instructions delivered into pet cells to guide the synthesis of specific therapeutic proteins or antigens. Its advantages include a short development cycle and flexible production, making it suitable for the rapid development of novel vaccines, protein replacement therapies, and emergency infectious disease prevention and control.
By leveraging the RNA interference mechanism, small interfering RNA precisely "silences" the expression of disease-causing genes in pets. This therapy is particularly suitable for treating hereditary or chronic diseases caused by the overexpression of specific genes. A single dose can produce long-lasting therapeutic effects, significantly reducing the frequency of administration.